Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Assessment of Response of Unresectable Hepatocellular Carcinoma to Combination Chemoembolization and Stereotactic Body Radiation Therapy

NCT02513199 is registered in ClinicalTrials.gov with Icahn School of Medicine at Mount Sinai as lead sponsor.

NCT NCT02513199
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02513199 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Assessment of Response of Unresectable Hepatocellular Carcinoma to Combination Chemoembolization and Stereotactic Body Radiation Therapy
Lead sponsor
Icahn School of Medicine at Mount Sinai
Phase
Phase 2
Overall status
Completed
Start date
November 30, 2014
Completion date
January 1, 2022
Enrollment
32 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hepatocellular carcinoma